Novo Nordisk A/S (Bagsværd, Denmark; www.novonordisk.com) has announced the acquisition of a U.S. manufacturing facility in West Lebanon, N.H., from Olympus Biotech. The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.
Novo Nordisk intends to use the facility for production of active pharmaceutical ingredients primarily for its portfolio of biopharmaceuticals. Some of the plant’s former employees have been offered jobs, which initially will focus on planning of the future plant setup. Final plans will determine potential and timing for future staffing increases. Novo Nordisk and Olympus Biotech have agreed not to disclose the terms of the acquisition.